Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
James L. Gulley, MD, PhD, chief of the Genitourinary Malignancies Branch, director of Medical Oncology Service, National Cancer Institute, discusses treatment beyond the second line in bladder cancer. Gulley says there is no standard procedure for the third line setting in bladder cancer, and that most oncologists would either turn to single-agent chemotherapy or to clinical trials.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More